My Cart
SanyouBio High-Yield mRNA In Vitro Prep Kit
Sanyou’s High-Yield mRNA In Vitro Synthesis Kit delivers an end-to-end solution for rapid, large-scale mRNA production, seamlessly integrating high-efficiency transcription with optional co-transcriptional capping within a single optimized workflow.
0.5-1.0 µg
Input DNA Quantity
90-100 µg
Output mRNA Quantity
>90%
Purity
Type | Catalog No. | Size | Catalog Price | Quantity | Stock |
|---|
Cap IN | KRA001 | 50 Reactions | ￥17080 | Inquiry | |
KRA002 | 100 Reactions | ￥32452 | Inquiry | ||
KRA005 | 1000 Reactions | ￥278235 | Inquiry | ||
NO Cap | KRA003 | 50 Reactions | ￥4505 | Inquiry | |
KRA004 | 100 Reactions | ￥8560 | Inquiry |
Sanyou’s High-Yield mRNA In Vitro Synthesis Kit delivers an end-to-end solution for rapid, large-scale mRNA production, seamlessly integrating high-efficiency transcription with optional co-transcriptional capping within a single optimized workflow. Designed to accelerate therapeutics development, vaccine research, gene editing, and protein production, the kit ensures consistently high mRNA purity (>95%), stability, and translational efficiency. Each 20-μL reaction generates up to 100 μg of RNA, with all necessary enzymes, nucleotides, and buffers included for robust in vitro synthesis.
1. mRNA Synthesis Process:
In vitro mRNA synthesis begins with a linear DNA template, RNA polymerase (e.g., T7), and nucleotide precursors.
The resulting transcript is purified and contains key structural elements: a 5′ cap, 5′ UTR, open reading frame (ORF), 3′ UTR, and poly(A) tail—all critical for stability and translation.
2. In Vivo Stability Challenges:
Despite its therapeutic potential, exogenous mRNA faces rapid degradation in vivo due to extracellular nucleases, macrophage clearance, and renal filtration—necessitating advanced delivery or chemical modifications for efficacy.
* Only in Cap IN version of kit.
Reagent | Item | Quantity (50 rxns) | Quantity (100 rxns) | Storage |
|---|
1 | 1x Reaction Buffer | 270 μL | 540 μL | -20 °C |
2 | ATP Solution, Sodium Solution, 7.5 mM | 90 μL | 90 μL | |
3 | CTP Solution, Sodium Solution, 7.5 mM | 90 μL | 90 μL | |
4 | GTP Solution, Sodium Solution, 7.5 mM | 90 μL | 90 μL | |
5 | UTP Solution, Sodium Solution , 7.5 mM | 90 μL | 90 μL | |
6 | RNA Polymerases, 7000 U/mL | 120 μL | 120 μL | |
7* | Cap1 Reagent, 6 mM | 72 μL | 72 μL | |
8 | DNase Inhibitor, RNase-free, 50 U/µL | 60 μL | 60 μL | |
9 | LiCl Precipitation Solution, 7.5 M | 1.65 mL | 1.65 mL | |
10 | Nuclease-free water | 5.5 mL | 5.5 mL | |
11 | Positive Control | 5 μg | 5 μg |
* Only in Cap IN kit.
Why Sanyou mRNA In Vitro Synthesis Kit ?
Feature | Advantages |
|---|
Optimized T7 RNA Polymerase | Ensures maximum transcription efficiency |
Co-transcriptional Capping | Mimics natural Cap 1 structure for better protein expression |
Impurity Removal | Reduces immune activation risks |
Liquid Format | Flexible storage and handling |
1. T7 RNA Polymerase Efficiency:
T7 RNA Polymerase enables high-yield mRNA synthesis and supports ultra-long transcript production—outperforming other polymerases.
2. 5′ Cap Importance:
An optimized 5′ cap enhances ribosome binding, significantly boosting mRNA translation efficiency.
3. Cap Stability Advantage:
Unlike uncapped RNA (degraded in 15 minutes), synthetic capped mRNA remains stable for over 48 hours.
4. Poly (A) Tail Function:
The poly(A) tail extends mRNA stability and translation efficiency, with longer tails correlating to prolonged activity and higher protein output.
Technical Specification
Parameter | Advantages |
|---|
Input Template | Linearized DNA (linearized plasmid or PCR product) |
Yield | Up to 0.1 mg/mL per reaction |
Purity | >90% (HPLC-verified) |
Capping Efficacy | >90% |
Storage | -20°C to 4°C (stable for 12 months) |
Applications | Vaccines, protein replacement, CAR-T, CRISPR, etc. |
Download the related documents for this product by clicking the logo.
SanyouBio High-Yield mRNA In Vitro Prep Kit
Sanyou’s High-Yield mRNA In Vitro Synthesis Kit delivers an end-to-end solution for rapid, large-scale mRNA production, seamlessly integrating high-efficiency transcription with optional co-transcriptional capping within a single optimized workflow.
0.5-1.0 µg
Input DNA Quantity
90-100 µg
Output mRNA Quantity
>90%
Purity
Type | Catalog No. | Size | Catalog Price | Quantity | Stock |
|---|
Cap IN | KRA001 | 50 Reactions | ￥17080 | Inquiry | |
KRA002 | 100 Reactions | ￥32452 | Inquiry | ||
KRA005 | 1000 Reactions | ￥278235 | Inquiry | ||
NO Cap | KRA003 | 50 Reactions | ￥4505 | Inquiry | |
KRA004 | 100 Reactions | ￥8560 | Inquiry |
Sanyou’s High-Yield mRNA In Vitro Synthesis Kit delivers an end-to-end solution for rapid, large-scale mRNA production, seamlessly integrating high-efficiency transcription with optional co-transcriptional capping within a single optimized workflow. Designed to accelerate therapeutics development, vaccine research, gene editing, and protein production, the kit ensures consistently high mRNA purity (>95%), stability, and translational efficiency. Each 20-μL reaction generates up to 100 μg of RNA, with all necessary enzymes, nucleotides, and buffers included for robust in vitro synthesis.
* Only in Cap IN version of kit.
Reagent | Item | Quantity (50 rxns) | Quantity (100 rxns) | Storage |
|---|
1 | 1x Reaction Buffer | 270 μL | 540 μL | -20 °C |
2 | ATP Solution, Sodium Solution, 7.5 mM | 90 μL | 90 μL | |
3 | CTP Solution, Sodium Solution, 7.5 mM | 90 μL | 90 μL | |
4 | GTP Solution, Sodium Solution, 7.5 mM | 90 μL | 90 μL | |
5 | UTP Solution, Sodium Solution , 7.5 mM | 90 μL | 90 μL | |
6 | RNA Polymerases, 7000 U/mL | 120 μL | 120 μL | |
7* | Cap1 Reagent, 6 mM | 72 μL | 72 μL | |
8 | DNase Inhibitor, RNase-free, 50 U/µL | 60 μL | 60 μL | |
9 | LiCl Precipitation Solution, 7.5 M | 1.65 mL | 1.65 mL | |
10 | Nuclease-free water | 5.5 mL | 5.5 mL | |
11 | Positive Control | 5 μg | 5 μg |
* Only in Cap IN kit.
1. mRNA Synthesis Process:
In vitro mRNA synthesis begins with a linear DNA template, RNA polymerase (e.g., T7), and nucleotide precursors.
The resulting transcript is purified and contains key structural elements: a 5′ cap, 5′ UTR, open reading frame (ORF), 3′ UTR, and poly(A) tail—all critical for stability and translation.
2. In Vivo Stability Challenges:
Despite its therapeutic potential, exogenous mRNA faces rapid degradation in vivo due to extracellular nucleases, macrophage clearance, and renal filtration—necessitating advanced delivery or chemical modifications for efficacy.
Why Sanyou mRNA In Vitro Synthesis Kit ?
Feature | Advantages |
|---|
Optimized T7 RNA Polymerase | Ensures maximum transcription efficiency |
Co-transcriptional Capping | Mimics natural Cap 1 structure for better protein expression |
Impurity Removal | Reduces immune activation risks |
Liquid Format | Flexible storage and handling |
1. T7 RNA Polymerase Efficiency:
T7 RNA Polymerase enables high-yield mRNA synthesis and supports ultra-long transcript production—outperforming other polymerases.
2. 5′ Cap Importance:
An optimized 5′ cap enhances ribosome binding, significantly boosting mRNA translation efficiency.
3. Cap Stability Advantage:
Unlike uncapped RNA (degraded in 15 minutes), synthetic capped mRNA remains stable for over 48 hours.
4. Poly (A) Tail Function:
The poly(A) tail extends mRNA stability and translation efficiency, with longer tails correlating to prolonged activity and higher protein output.
Technical Specification
Parameter | Advantages |
|---|
Input Template | Linearized DNA (linearized plasmid or PCR product) |
Yield | Up to 0.1 mg/mL per reaction |
Purity | >90% (HPLC-verified) |
Capping Efficacy | >90% |
Storage | -20°C to 4°C (stable for 12 months) |
Applications | Vaccines, protein replacement, CAR-T, CRISPR, etc. |
Download the related documents for this product by clicking the logo.
